On October 12, 2023, IN8bio, a pioneering clinical-stage biopharmaceutical company, made a significant announcement regarding its gamma-delta T cell therapies.
The company has successfully completed the enrollment for its Phase 1 study of INB-100, a potential treatment for leukemia patients. This marks a significant step forward as INB-100 is being evaluated for its safety when administered to leukemia patients post-hematopoietic stem cell transplantation.
Furthermore, IN8bio has initiated the enrollment process for its Phase 2 clinical trial, which will evaluate INB-400’s efficacy in treating newly diagnosed glioblastoma multiforme (GBM), a particularly aggressive form of brain cancer.
This move is in line with the company’s mission to achieve “Cancer Zero” by harnessing the immune system’s power to develop innovative therapies that can eradicate cancer.
William Ho, the Co-founder and CEO of IN8bio, expressed his optimism about the company’s novel immunotherapy approach. He mentioned that the early clinical results have shown promise, especially for patients with unmet medical needs.
The company is eager to explore the full potential of gamma-delta T cells as a viable treatment option for both solid and hematological cancers.
Key Highlights:
- Phase 1 Clinical Trial of INB-100 in Leukemia: The primary focus of this trial is to assess the safety and tolerability of INB-100. Preliminary data presented in April 2023 revealed that all evaluable patients treated with INB-100 remained alive and in complete remission. A comprehensive clinical update is expected to be presented at the 65th ASH Annual Meeting in December 2023.
- Phase 2 Clinical Trial of INB-400 in GBM: The primary goal of this trial is to determine the 12-month overall survival rate of patients treated with INB-400. The FDA granted INB-400 the Orphan Drug Designation in April 2023, making it the first genetically modified gamma-delta T cell therapy to receive this recognition.
- About IN8bio: IN8bio is at the forefront of discovering and developing gamma-delta T cell product candidates for various tumors. Their DeltEx platform employs multiple approaches, including allogeneic, autologous, and genetically modified, to develop effective cell therapies.
IN8bio’s recent advancements have the potential to reshape the treatment landscape for leukemia and GBM, offering hope to countless patients worldwide.